|
Migraine Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The neuropeptide CGRP, acting through the G-protein coupled receptor CALCRL and its coreceptor RAMP1, plays a key role in migraines, which has led to the clinical development of several inhibitory compounds.
|
31756985 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Understanding the biology of migraine through careful bench-based research has led to major classes of therapeutics being identified: triptans, serotonin 5-HT<sub>1B/1D</sub> receptor agonists; gepants, calcitonin gene-related peptide (CGRP) receptor antagonists; ditans, 5-HT<sub>1F</sub> receptor agonists, CGRP mechanisms monoclonal antibodies; and glurants, mGlu<sub>5</sub> modulators; with the promise of more to come.
|
28179394 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We will further discuss the therapeutic agents which have appeared in the most recent years for migraine care, from calcitonin gene-related peptide (CGRP) receptor antagonists, gepants; through serotonin 5-HT<sub>1F</sub> receptor agonists, ditans, and CGRP or CGRP receptor monoclonal antibodies to invasive and non-invasive neuromodulation techniques.
|
28321564 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP receptor inhibitors and anti-CGRP antibodies have been demonstrated to be therapeutically effective in migraine.
|
29335794 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The US Food and Drug Administration (FDA) approved erenumab-aooe, an anti-CGRP receptor monoclonal antibody, for the prevention of migraine on May 17, 2018.
|
30403405 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The evolution of CGRP migraine science gave impetus to the development of peripherally acting drugs that could modulate CGRP chronically to prevent frequent episodic and chronic migraine.
|
31020659 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent advances in the biology of the cerebellum indicate that there may be a role in nociception; hence a target of the recently discovered CGRP receptor antagonists that have demonstrated improvement in migraine pain and associated symptoms could be cerebellar CGRP receptors.
|
21040789 |
2011 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical trials carried out during the past decade have proved that CGRP receptor antagonists are effective for treating migraine, and antibodies to the receptor and CGRP are currently under investigation.
|
25340934 |
2015 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the efficacy of fremanezumab, a selective monoclonal CGRP ligand antibody, during the first 3 weeks of therapy in patients with high-frequency episodic migraine (HFEM) to relieve migraine headaches and associated symptoms and to reduce use of acute migraine medications.
|
30450545 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Background:</b> Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine.
|
31354502 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CLR/RAMP1, or CGRP receptor, antagonists have been developed for the treatment of migraine headache and osteoarthritis pain; whereas CLR/RAMP2, or ADM receptor, antagonists are being developed for the treatment of tumor growth/metastasis.
|
31150417 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine.
|
31159727 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The first anti-CGRP treatment, an intravenous CGRP-receptor antagonist or gepant, olcegepant, was described as effective in terminating migraines in humans in 2004.
|
30242830 |
2018 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the progresses in migraine management have been reached with the development of emerging agonists of 5-HT receptors and novel antagonists of CGRP receptors.
|
31208068 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The CGRP Pathway in Migraine as a Viable Target for Therapies.
|
29697153 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed a close relationship between the CGRP containing C-fibers and the Aδ-fibers containing the CGRP-receptor elements, suggesting a point of axon-axon interaction for the released CGRP and a site of action for gepants and the novel mAbs to alleviate migraine.
|
31718551 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review.
|
31547694 |
2020 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The blockade of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the interruption of trigeminal nerve system-mediated headache syndromes such as migraine.
|
29623520 |
2018 |
|
Migraine Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Methods Following sumatriptan priming to model MOH, rats were hyper-responsive to environmental stress, demonstrating delayed cephalic and extracephalic allodynia and increased levels of CGRP in the jugular blood, consistent with commonly observed clinical outcomes during migraine.
|
28376659 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache.
|
28644160 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
ECL2 is fundamental for ligand-induced activation of the calcitonin gene related peptide (CGRP) receptor, a family B GPCR implicated in migraine and heart disease.
|
28572046 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
|
29020807 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
These data implicate the dura mater as a primary location of action for CGRP in migraine and suggest that female-specific mechanisms downstream of CGRP receptor activation contribute to the higher prevalence of migraine in women.
|
30962278 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel therapeutic perspectives in migraine includes biotechnological drugs directed against molecules (such as CGRP and its receptor) that cause vasodilatation at the peripheral level of the meningeal blood vessels and reflex stimulation of the parasympathetic system.
|
31101004 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
As reviewed in this manuscript, a number of small molecule antagonists of the CGRP receptor have been developed for migraine therapy.
|
29556965 |
2018 |